Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status

Gynecologic Oncology

Volumn 75, Issue 2, 1999, Pages 261-266

  Wolf, Judith K ^a   Mills, Gordon B ^a   Bazzet, Lisa ^b   Bast Jr , Robert C ^a   Roth, Jack A ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Gene therapy; Ovarian cancer; Wild type p53

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; MUTANT PROTEIN; PROTEIN P53;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; GENE CASSETTE; GENE INSERTION; GENE MUTATION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; POLYADENYLATION; PRIORITY JOURNAL; SIMIAN VIRUS 40; TUMOR SUPPRESSOR GENE;

EID: 0032740431     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5565     Document Type: Article

References (30)

1. American Cancer Society, Facts and Figures, 1998.
2. Vogelstein B, Fearon E R, Hamilton S R, Kern S E, Preisinger A C, Leppert M, Nakamura Y, White R, Smits A M, Bos J L. Genetic alterations during colorectal-tumor development. N Engl J Med. 319:1988;525-532.
3. Rodrigues N R, Rowan A, Smith M E, Kerr I B, Bodmer W F, Gannon J V, Lane D P. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA. 7:1990;7555-7559.
4. Bartek J, Iggo R, Gannon J, Lane D P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 5:1990;893-899.
5. Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Cancer Res. 52:1992;734-736.
6. Teneriello M G, Ebina M, Linnoila R I, Henry M, Nash J D, Park R C, Birrer M J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53:1993;3103-3108.
7. Berchuck A, Kohler M F, Hopkins M P, Humphrey P A, Robboy S J, Rodriguez G C, Soper J T, Clarke-Pearson D L, Bast R C. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol. 52:1994;232-236.
8. Mok S C, Bell D A, Knapp R C, Fishbaugh P M, Welch W R, Muto M G, Berkowitz R S, Tsao S W. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53:1993;1489-1492.
9. Hamada K, Zhang W-W, Alemany R, Wolf J, Roth J A, Follen-Mitchell M. Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro. Gynecol Oncol. 60:1996;373-379.
10. Baker S J, Markowitz S, Fearon E R, Wilson J K, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington, DC). 253:1991;49-53.
11. Cai D W, Mukhopadhyay T, Liu Y, Fujiwara T, Roth J A. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gen Ther. 4:1993;617-624.
12. Liu T-J, Zhang W-W, Taylor D L, Roth J A, Goepfert H, Clayman G L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 54:1994;3662-3667.
13. Korzarsky K F, Wilson J M. Gene therapy: adenovirus vectors. Curr Opin Gene Dev. 3:1993;499-503.
14. Santoso J T, Tang D-C, Lane S B, Hung J, Reed D J, Muller C Y, Carbone D P, Lucci J A 3rd, Miller D S, Mathis J M. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol. 59:1995;171-178.
15. Mujoo K, Maneval D C, Anderson S C, Gutterman J U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 12:1996;1617-1623.
16. Zhang W-W, Fang X, Mazur W, French B A, Georges R N, Roth J A. High-efficiency gene transfer and high level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gen Ther. 1:1994;1-10.
17. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 54:1992;1169-1174.
18. Hurteau J, Rodriguez G C, Whitaker R S, Shah S, Mills G, Bast R C, Berchuck A. Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer. 74:1994;93-99.
19. Bast R C Jr, Boyer C M, Jacobs I, Xu F J, Wu S, Weiner J, Kohler M, Berchuck A. Cell growth regulation in epithelial ovarian cancer. Cancer. 71:1993;1597-1601.
20. Lanfancone L, Pelicci P G. Cancer genetics. Curr Opin Gene Dev. 4:1994;109-119.
21. Fujiwara T, Grimm E A, Roth J A. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol. 6:1994;96-105.
22. Bergelson J M, Cunningham J A, Droguett G, Kurt-Jones E A, Krithivas A, Hong J S, Horwitz M S, Crowell R L, Finberg R W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 275:1997;1320-1323.
23. Sweet R W, Yokoyama S, Kamata T, Feramisco J R, Rosenberg M, Gross M. The product of ras is a GTPase and the T24 oncogene mutant is deficient in this activity. Nature. 311:1984;273-275.
24. Scambia G, Catozzi L, Panici P B, Ferrandina G, Coronetta F, Barozzi R, Baiocchi G, Uccelli L, Piffanelli A, Mancuso S. Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor. Am J Obstet Gynecol. 168:1993;71-78.
25. Liu T-J, el-Naggar A K, McDonnell T J, Steck K D, Wang M, Taylor D, Clayman G L. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 55:1995;3117-3122.
26. von Gruenigen V E, Santoso J T, Coleman R L, Muller C Y, Miller D S, Mathis J M. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol. 69:1998;197-204.
27. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA. 89:1992;4495-4499.
28. Fujiwara T, Grimm E A, Mukhopadhyay T, Cai D W, Owen-Schaub L B, Roth J A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53:1993;4129-4133.
29. Donehower L A, Harvey M, Slagle B L, McArthur M J, Montgomery C A Jr, Butel J S. Mice deficient in p53 are developmentally normal, but susceptible to spontaneous tumors. Nature (London). 356:1992;215-221.
30. 1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.